SHR-0532

It’s only fair to share… SHR-0532 CAS 2166329-09-3 C24 H26 N4 O5 . C4 H6 O6 2-Pyridinecarboxamide, 5-cyano-N-[1-[(2R)-2-(1,3-dihydro-4-methyl-1-oxo-5-isobenzofuranyl)-2-hydroxyethyl]-4-piperidinyl]-4-methoxy-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) FREE FORM 1945997-37-4 C24 H26 N4 O5 450.49 2-Pyridinecarboxamide, 5-cyano-N-[1-[(2R)-2-(1,3-dihydro-4-methyl-1-oxo-5-isobenzofuranyl)-2-hydroxyethyl]-4-piperidinyl]-4-methoxy- 5-Cyano-N-[1-[(2R)-2-(1,3-dihydro-4-methyl-1-oxo-5-isobenzofuranyl)-2-hydroxyethyl]-4-piperidinyl]-4-methoxy-2-pyridinecarboxamide KCNJ potassium channel-1 inhibitor, Hypertension; Renal insufficiency Originator Jiangsu Hengrui Medicine Co. Class Antihypertensives Mechanism of Action Undefined mechanism Preclinical Hypertension 03 Jun 2019 Jiangsu Hengrui Medicine Co. plans a phase I trial for Hypertension (PO) in June 2019 (NCT03971929) …

SEVITERONEL, севитеронел , سيفيتيرونيل , 赛维罗奈 ,

It’s only fair to share… SEVITERONEL CAS Registry Number 1610537-15-9 Molecular formulaC18 H17 F4 N3 O3, MW 399.34 1H-1,2,3-Triazole-5-methanol, α-[6,7-bis(difluoromethoxy)-2-naphthalenyl]-α-(1-methylethyl)-, (αS)- (αS)-α-[6,7-Bis(difluoromethoxy)-2-naphthalenyl]-α-(1-methylethyl)-1H-1,2,3-triazole-5-methanol 8S5OIN36X4 севитеронел [Russian] [INN] سيفيتيرونيل [Arabic] [INN] 赛维罗奈 [Chinese] [INN] Mechanism of ActionAndrogen receptor antagonists; Estrogen receptor antagonists; Steroid 17-alpha-hydroxylase inhibitors; Steroid 17-alpha-hydroxylase modulators WHO ATC codeL01 (Antineoplastic Agents)L01X-X (Other antineoplastic agents) EPhMRA codeL1 (Antineoplastics)L1X9 (All other antineoplastics) 1H-1,2,3-Triazole-5-methanol, alpha-(6,7-bis(difluoromethoxy)-2-naphthalenyl)-alpha-(1-methylethyl)-, (alphaS)- …

FDA approves new treatment Victoza (liraglutide) for pediatric patients with type 2 diabetes

It’s only fair to share…     The U.S. Food and Drug Administration today approved Victoza (liraglutide) injection for treatment of pediatric patients 10 years or older with type 2 diabetes. Victoza is the first non-insulin drug approved to treat type 2 diabetes in pediatric patients since metformin was approved for pediatric use in 2000. …

VX-445, Elexacaftor, エレクサカフトル

It’s only fair to share… VX-445, Elexacaftor, エレクサカフトル 597.658 g/mol, C26H34F3N7O4S 3-Pyridinecarboxamide, N-((1,3-dimethyl-1H-pyrazol-4-yl)sulfonyl)-6-(3-(3,3,3-trifluoro-2,2-dimethylpropoxy)-1H-pyrazol-1-yl)-2-((4S)-2,2,4-trimethyl-1-pyrrolidinyl)- N-[(1,3-Dimethyl-1H-pyrazol-4-yl)sulfonyl]-6-[3-(3,3,3-trifluoro-2,2-dimethylpropoxy)-1H-pyrazol-1-yl]-2-[(4S)-2,2,4-trimethyl-1-pyrrolidinyl]-3-pyridinecarboxamide 3-Pyridinecarboxamide, N-((1,3-dimethyl-1H-pyrazol-4-yl)sulfonyl)-6-(3-(3,3,3-trifluoro-2,2-dimethylpropoxy)-1H-pyrazol-1-yl)-2-((4S)-2,2,4-trimethyl-1-pyrrolidinyl)- UNII-RRN67GMB0V RRN67GMB0V VX-445 WHO 11180 Cas 2216712-66-0 WHO 11180 Treatment of cystic fibrosis, CFTR modulator Elexacaftor is under investigation in clinical trial NCT03525548 (A Study of VX-445 Combination Therapy in CF Subjects Homozygous for F508del (F/F)). Cystic fibrosis transmembrane conductance regulator (CFTR) corrector …

MITAPIVAT

It’s only fair to share… MITAPIVAT CAS 1260075-17-9 MF C24H26N4O3S MW 450.55 8-Quinolinesulfonamide, N-[4-[[4-(cyclopropylmethyl)-1-piperazinyl]carbonyl]phenyl]- N-[4-[[4-(Cyclopropylmethyl)-1-piperazinyl]carbonyl]phenyl]-8-quinolinesulfonamide Originator Agios Pharmaceuticals Class Antianaemics; Piperazines; Quinolines; Small molecules; Sulfonamides Mechanism of Action Pyruvate kinase stimulants Orphan Drug Status Yes – Inborn error metabolic disorders New Molecular Entity Yes Phase III Inborn error metabolic disorders Phase II  Thalassaemia 27 Feb 2019 Agios Pharmaceuticals plans a phase III trial for …

ABACAVIR

It’s only fair to share… Abacavir CAS Registry Number: 136470-78-5 CAS Name: (1S,4R)-4-[2-Amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol Additional Names: (-)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol Manufacturers’ Codes: 1592U89 Molecular Formula: C14H18N6O Molecular Weight: 286.33 Percent Composition: C 58.73%, H 6.34%, N 29.35%, O 5.59% Literature References: Nucleoside reverse transcriptase inhibitor (NRTI). Prepn: S. M. Daluge, EP 349242 (1990 to Wellcome Found.); idem, US 5034394 (1991 to Burroughs Wellcome). Asymmetric synthesis: M. T. Crimmins, B. W. King, J. Org. Chem. 61,4192 (1996). …

FDA approves new treatment for hospital-acquired and ventilator-associated bacterial pneumonia

It’s only fair to share… The U.S. Food and Drug Administration today approved a new indication for the previously FDA-approved drug, Zerbaxa (ceftolozane and tazobactam) for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) in patients 18 years and older. The FDA initially approved Zerbaxa in 2014 to treat complicated intra-abdominal infections …

Onasemnogene abeparvovec オナセムノジーンアベパルボベック

It’s only fair to share…   Onasemnogene abeparvovec オナセムノジーンアベパルボベック DNA (synthetic adeno-associated virus 9 vector scAAV9.CB.hSMN human survivor motor neuron protein-specifying) Zolgensma FDA 2019/5/24 APPROVED CAS: 1922968-73-7 AVXS-101 Spinal muscular atrophy treatment Treatment of Spinal Muscular Atrophy (SMA) Type 1 Gene therapy product Onasemnogene abeparvovec, sold under the trade name Zolgensma, is a gene therapy medication used to treat spinal muscular atrophy (SMA). …

FDA approves first PI3K inhibitor Piqray (alpelisib) for breast cancer

It’s only fair to share… FDA approves first PI3K inhibitor for breast cancer syn https://newdrugapprovals.org/2018/06/25/alpelisib-byl-719/ Today, the U.S. Food and Drug Administration approved Piqray (alpelisib) tablets, to be used in combination with the FDA-approved endocrine therapy fulvestrant, to treat postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced …

CT-1812

It’s only fair to share…   CT-1812 Elayta Condition(s): Alzheimer’s Disease U.S. FDA Status: Alzheimer’s Disease (Phase 2) Company: Cognition Therapeutics Inc. CAS: 1802632-22-9 Chemical Formula: C24H33NO4S Molecular Weight: 431.591 2-(tert-butoxy)-4-(3-methyl-3-(5-(methylsulfonyl)isoindolin-2-yl)butyl)phenol Phenol, 4-[3-[1,3-dihydro-5-(methylsulfonyl)-2H-isoindol-2-yl]-3-methylbutyl]-2-(1,1-dimethylethoxy)- Originator Cognition Therapeutics Class Antidementias; Neuroprotectants; Nootropics; Small molecules Mechanism of Action Sigma-2 receptor antagonists Phase II Alzheimer’s disease Phase I Cognition disorders 21 Feb 2019 Cognition Therapeutics receives patent for …